Luminex Posts 13 Percent Revenue Growth for Q1 | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday first-quarter revenue grown of 13 percent driven by a sharp uptick in assay revenues.

The Austin, Texas-based molecular diagnostics developer reported total revenues of $48.7 million for the quarter ended March 31, compared to revenues of $43.3 million for the first quarter of 2011. It beat Wall Street's consensus estimate of $48.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.